

No. 10-49

September 17, 2010
Eisai Co., Ltd.

**FDA ACCEPTS ARICEPT[®] PATCH (DONEPEZIL TRANSDERMAL SYSTEM)
NDA FOR REVIEW**

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai")

[Notes to Editors]

Overview of Eisai's partnership with Teikoku Seiyaku and Teikoku USA

In February 2010, Eisai Co., Ltd. concluded license and option agreements with Teikoku Seiyaku and Teikoku USA regarding the development and marketing of a patch formulation of donepezil, an overview of which is as follows:

United States: Development by Teikok